Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial

Davies, 2002, Mutations of the BRAF gene in human cancer, Nature, 417, 949, 10.1038/nature00766

Curtin, 2005, Distinct sets of genetic alterations in melanoma, N Engl J Med, 353, 2135, 10.1056/NEJMoa050092

Chapman, 2011, Improved survival with vemurafenib in melanoma with BRAF V600E mutation, N Engl J Med, 364, 2507, 10.1056/NEJMoa1103782

Hauschild, 2012, Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial, Lancet, 380, 358, 10.1016/S0140-6736(12)60868-X

McArthur, 2014, Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study, Lancet Oncol, 15, 323, 10.1016/S1470-2045(14)70012-9

Hauschild, 2015, An update on overall survival (OS) and follow-on therapies in BREAK, a phase II randomized trial:dabrafenib(D) dacarbazine (DTIC) in patients (PTS) with BRAF V600E, Ann Oncol, 25

Johannessen, 2010, COT drives resistance to RAF inhibition through MAP kinase pathway reactivation, Nature, 468, 968, 10.1038/nature09627

Villanueva, 2010, Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K, Cancer Cell, 18, 683, 10.1016/j.ccr.2010.11.023

Poulikakos, 2011, RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E), Nature, 480, 387, 10.1038/nature10662

Shi, 2014, Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy, Cancer Discov, 4, 80, 10.1158/2159-8290.CD-13-0642

Trunzer, 2013, Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma, J Clin Oncol, 31, 1767, 10.1200/JCO.2012.44.7888

Ribas, 2014, Combination of vemurafenib and cobimetinib in patients with advanced BRAFV600-mutated melanoma: a phase 1b study, Lancet Oncol, 15, 954, 10.1016/S1470-2045(14)70301-8

Larkin, 2014, Combined vemurafenib and cobimetinib in BRAF-mutated melanoma, N Engl J Med, 371, 1867, 10.1056/NEJMoa1408868

Balch, 2009, Final version of 2009 AJCC melanoma staging and classification, J Clin Oncol, 27, 6199, 10.1200/JCO.2009.23.4799

Bucheit, 2013, Clinical characteristics and outcomes with specific BRAF and NRAS mutations in patients with metastatic melanoma, Cancer, 119, 3821, 10.1002/cncr.28306

Long, 2014, Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma, N Engl J Med, 371, 1877, 10.1056/NEJMoa1406037

Long, 2015, Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial, Lancet, 386, 444, 10.1016/S0140-6736(15)60898-4

Robert, 2015, Improved overall survival in melanoma with combined dabrafenib and trametinib, N Engl J Med, 372, 30, 10.1056/NEJMoa1412690

Eisenhauer, 2009, New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1), Eur J Cancer, 45, 228, 10.1016/j.ejca.2008.10.026

Ishibashi, 2003, Sex steroid hormone receptors in human thymoma, J Clin Endocrinol Metab, 88, 2309, 10.1210/jc.2002-021353

Aaronson, 1993, The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology, J Natl Cancer Inst, 85, 365, 10.1093/jnci/85.5.365

Ascierto, 2013, Ipilimumab in the treatment of metastatic melanoma: a summary of recent studies, Tumori, 99, 302e, 10.1177/030089161309900625

Diem, 2015, Prognostic score for patients with advanced melanoma treated with ipilimumab, Eur J Cancer, 51, 2785, 10.1016/j.ejca.2015.09.007

Robert, 2015, Eur J Cancer, 51, S663, 10.1016/S0959-8049(16)31820-2

Kelderman, 2014, Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma, Cancer Immunol Immunother, 63, 449

Pavlick, 2015, Extended follow-up results of phase Ib study (BRIM7) of vemurafenib (VEM) with cobimetinib (COBI) in BRAF-mutant melanoma, J Clin Oncol, 33

Dreno B, Ribas A, Larkin J, et al. Incidence, course, and management of toxicities associated with vemurafenib and cobimetinib in the coBRIM study. Society for Melanoma Research 2014; Zurich, Switzerland; Nov 13–16, 2014.

Yan, 2014, Vemurafenib and cobimetinib potently inhibit PS6 signaling in BRAFV600 mutation-positive locally advanced or metastatis melanoma from BRIM7 study, Ann Oncol, 25, iv378, 10.1093/annonc/mdu344.9

2015

2015

2016

2016